Morgan Stanley set a GBX 1,600 ($21.26) target price on GlaxoSmithKline plc (LON:GSK) in a report published on Wednesday morning. The firm currently has a sell rating on the stock.

GSK has been the topic of several other research reports. J P Morgan Chase & Co reiterated a neutral rating and issued a GBX 1,570 ($20.86) price objective on shares of GlaxoSmithKline plc in a report on Monday, October 2nd. Liberum Capital cut their price objective on GlaxoSmithKline plc from GBX 1,900 ($25.25) to GBX 1,760 ($23.39) and set a buy rating on the stock in a report on Wednesday, October 4th. Goldman Sachs Group, Inc. (The) set a GBX 1,900 ($25.25) price objective on GlaxoSmithKline plc and gave the company a buy rating in a report on Wednesday, July 26th. BNP Paribas set a GBX 1,620 ($21.53) price objective on GlaxoSmithKline plc and gave the company a neutral rating in a report on Wednesday, September 6th. Finally, Barclays PLC reiterated an equal weight rating and issued a GBX 1,550 ($20.60) price objective on shares of GlaxoSmithKline plc in a report on Thursday, July 27th. Four research analysts have rated the stock with a sell rating, eleven have issued a hold rating and seven have issued a buy rating to the company. The stock has an average rating of Hold and a consensus price target of GBX 1,690.67 ($22.46).

Shares of GlaxoSmithKline plc (GSK) traded up 0.16% during trading on Wednesday, hitting GBX 1536.00. The stock had a trading volume of 8,848,806 shares. The stock’s market cap is GBX 75.08 billion. The company’s 50 day moving average price is GBX 1,501.97 and its 200 day moving average price is GBX 1,580.88. GlaxoSmithKline plc has a 12 month low of GBX 1,444.00 and a 12 month high of GBX 1,724.50.

TRADEMARK VIOLATION WARNING: “GlaxoSmithKline plc (GSK) Given a GBX 1,600 Price Target at Morgan Stanley” was first posted by Watch List News and is the property of of Watch List News. If you are viewing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this article can be accessed at https://www.watchlistnews.com/glaxosmithkline-plc-gsk-given-a-gbx-1600-price-target-at-morgan-stanley/1641646.html.

The firm also recently announced a dividend, which was paid on Thursday, October 12th. Stockholders of record on Thursday, August 10th were paid a dividend of GBX 19 ($0.25) per share. This represents a dividend yield of 1.23%. The ex-dividend date was Thursday, August 10th.

In other GlaxoSmithKline plc news, insider Simon Dingemans bought 1,076 shares of the business’s stock in a transaction dated Thursday, October 12th. The stock was acquired at an average cost of GBX 1,527 ($20.29) per share, with a total value of £16,430.52 ($21,831.68). Also, insider Manvinder Singh Banga bought 2,267 shares of the business’s stock in a transaction dated Wednesday, July 26th. The shares were acquired at an average cost of GBX 1,599 ($21.25) per share, with a total value of £36,249.33 ($48,165.47). Over the last three months, insiders have bought 3,368 shares of company stock valued at $5,305,807.

About GlaxoSmithKline plc

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline plc (LON:GSK)

Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with Analyst Ratings Network's FREE daily email newsletter.